Previous studies have reported that PANDAR was significantly upregulated in cholangiocarcinoma (CCA) patients21, bladder cancer patients22, clear cell renal cell carcinoma (ccRCC) patients23, hepatocellular carcinoma24 and colorectal cancer patients25. Here, PANDAR is linked to cholangiocarcinoma.